Rat Heart / Stomach / Striated muscle slides

TEST LIMITATIONS
1. No diagnosis should be based upon a single serologic test result since various host factors must be taken into consideration.
2. It has been found that some strains of streptococcus cross-react with cardiac antigens.
3. Heart muscle or pericardial tissue damage due to surgery or stab wounds can produce CMA.
4. More than one mechanism may be involved in MG. Factors like sex, age, presence or absence of thymoma, other autoantibodies, HLA type, response to thymectomy and/or immunosuppressive drugs must be considered in addition to the detection of anti-AChR and anti-Str antibodies.

LITERATURE REFERENCES

SUMMARY AND EXPLANATION
Demonstration of Cardiac Muscle Antibody (CMA) by utilising the indirect fluorescent antibody method enables serologic assessment or possible detection of cardiac disease. The presence of a (histologically defined) circulating antibody to one or more of the cardiac muscle antigens can aid in patient diagnosis and prognosis of diseases such as rheumatic fever, myocardial infarction and a variety of post-cardiomyopathy states. The substrate utilised in this kit is sections of rat heart although monkey heart sections are also available. Clinical and experimental evidence strongly suggests that circulating antibodies directed against acetylcholine receptor (AChR) and muscle cell antigens are important in the pathogenesis of myasthenia gravis. Tests for detection of antibodies to AChR and muscle cell antigens can be of diagnostic value. High titres of anti-AChR and anti-striated (Str) muscle antibodies define MG patients with thymoma. The absence of anti-AChR or anti-Str antibodies effectively excludes MG or thymoma respectively. Because antibody titre to either AChR or Str muscle corresponds only approximately to clinical status, their detection does not have direct prognostic value. Indirect immunofluorescence (IFA) is used for detection of anti-striated antibodies using acetone fixed longitudinal sections of skeletal muscle. Normal human sera can react with skeletal muscle in dilutions up to 1:30. A suggested screening dilution of 1:40 is recommended to increase specificity.

Smooth muscle antibodies (SMA) can be demonstrated in patients with acute and chronic hepatitis; the highest titres occurring in chronic active hepatitis (CAH). Most forms of chronic liver disease show SMA titres not higher than 1/160, except for CAH where titres up to 1/1280 are found. SMA is also found in approximately 50% of patients with primary biliary cirrhosis (PBC) and in up to 28% of patients with cryptogenic cirrhosis. SMA is rarely found (less than 2%) in patients with bile duct obstruction, alcoholic cirrhosis, lupus erythematosus and in the normal population. Rat stomach is utilised for SMA detection.

PRINCIPLE OF THE TEST
Diluted human sera are incubated on the tissue sections. The primary test reaction involves circulating antibodies present in the patient's serum, which attach to their homologous antigens. This occurs during the incubation period while the serum covers the antigen surface. A rinsing period is followed by a secondary reaction. The reagent used in the secondary reaction is a fluorescein labelled anti-human globulin conjugate. The antigen surface is then thoroughly rinsed free of unbound conjugate and viewed under an appropriate fluorescent microscope to visually identify various morphological patterns of nuclear fluorescence. With a positive reaction, the nuclear pattern appears apple-green when viewed under a fluorescent microscope, whilst a negative reaction appears black or greensh-black.

Bio-Diagnostics Ltd, Upton Industrial Estate, Rectory Road, Upton-upon-Severn, Worcestershire, WR8 0LX, United Kingdom. +44 (0) 1684 592262 email: enquiries@bio-diagnostics.co.uk
Rat Heart / Stomach / Striated muscle slides

WARNINGs AND PRECAUTIONs
1. Do not use slides beyond their expiration date.
2. Follow the procedural instructions exactly as they appear in this insert to ensure valid results.
3. For in vitro diagnostic use.
4. Handle slides by the edges since direct pressure on the antigen wells may damage the antigen.
5. Once the procedure has started do not allow the antigen in the wells to dry out. This may result in false negative test results, or unnecessary artefacts.

MATERIALS PROVIDED / STORAGE & STABILITY

SLIDE Rat heart / stomach / striated slides (T4001 / T8001 / T5001 / T0001)
The substrate antigen slides must be stored at 2-8°C upon receipt. Check label for expiration date.

ADDITIONAL MATERIALS REQUIRED BUT NOT PROVIDED
FITC Conjugate (BioDiagnostics J500 or J501).
Negative and positive controls (BioDiagnostics C000N, C005,C011, C015N).
Mounting Medium (BioDiagnostics R005).
Phosphate Buffered Saline (PBS) (BioDiagnostics R002).
Test tubes and rack or microtitre system
Disposable pipettes
Staining Dish and Slide Forceps
Volumetric Flask (500 ml)
Moisture Chamber
Distilled Water
Fluorescence Microscope
Paper Towels – lint free

All reagents required are available from BioDiagnostics Ltd - see catalogue for details.

KEY FOR OTHER SYMBOLS
Used in this instruction leaflet and on accompanying product packaging:
Manufacturer 
Contains sufficient for <n> tests
RFU Ready for use
Temperature limitation IVD In vitro diagnostic medical device

SPECIMEN COLLECTION
Serological specimens should be collected under aseptic conditions. Haemolysis is avoided through prompt separation of the serum from the clot. Serum should be stored at 2-8°C if it is to be analysed within a few days. Serum may be held for 3 to 6 months by storage at -20°C or lower. Lipaemic and strongly haemolytic serum should be avoided. When specimens are shipped at ambient temperatures, addition of a preservative such as 0.01% thiomersal or 0.1% sodium azide is strongly recommended.

TEST INSTRUCTIONS
1. Once slides reach room temperature tear slide envelope at notch. Carefully remove the slide and avoid touching the antigen areas. The slide is now ready to use.
2. Place a drop of diluted serum (20 to 30µl) and controls over the antigen wells.
3. Place slide with patient’s serum and controls in a moist chamber for 30 minutes at room temperature (approximately 18-24°C).
4. Remove slide from moisture chamber and tap the slide on its side to allow the serum to run off onto a piece of paper towel. Using a wash bottle, gently rinse remaining sera from slide being careful not to aim the rinse stream directly onto the well.
5. Wash in PBS for 5 minutes. Repeat using fresh PBS.
6. Remove slide from PBS and carefully wipe the underneath and around the wells with dry lint free paper towel. Apply sufficient pressure to slide while wiping to absorb buffer. Do not allow tissue to dry.
7. Deliver 1 drop (20-30µl) of conjugate per antigen well. Repeat steps 3-6.
8. Place 4-5 drops of mounting medium on slide.
9. Apply a 22 x 70 mm coverslip. Examine the slide under a fluorescent microscope.

Note: To maintain fluorescence, store mounted slide in a moisture chamber placed in a dark refrigerator.

QUALITY CONTROL
1. Positive and negative serum controls must be included in each day’s testing to confirm reproducibility, sensitivity and specificity of the test procedure.
2. In addition to positive and negative serum controls, a PBS control should be run to establish that the conjugate is free from non-specific staining of the antigen substrate. If the antigen shows bright fluorescence in the PBS control repeat using fresh conjugate. If the antigen still fluoresces, either the conjugate or antigen may be at fault.

RESULTS
Cardiac muscle:
1. Diffuse low level staining throughout the tissue is considered non-specific and should be considered negative.
2. Sarcolemmal-subsarcolemmal (SSL) staining is considered positive.
3. Intermyofibrillar (IMF) staining is considered positive. Staining of the SSL and/or the IMF type are both considered positive and can appear together or separately in the previously described instances
4. Titre Interpretation: The titre is the highest dilution of the patient’s serum showing a weak 1+ fluorescence in the PBS control repeat using fresh conjugate. If the antigen still fluoresces, either the conjugate or antigen may be at fault.

Rat Heart / Stomach / Striated muscle slides

Smoooth muscle antibody (SMA) positive results are observed as bright diffuse cytoplasmatic staining of the smooth muscle layers of the muscular mucosae in the rat stomach. Fluorescence may also be evident in the capillary walls of the gastric layer and surrounding arteries or veins. Fluorescence of the other cellular antigens such as nucleioli, parietal cells or connective tissue should not be reported as positive SMA.

The titre is the highest dilution of the patient’s serum showing weak (1+) fluorescence of the muscular mucosa,

<table>
<thead>
<tr>
<th>Titre</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/10</td>
<td>Normal, negative</td>
</tr>
<tr>
<td>1/20-1/80</td>
<td>Positive, suggestive of liver disease</td>
</tr>
<tr>
<td>1/160 or greater</td>
<td>Suggestive of active chronic hepatitis</td>
</tr>
</tbody>
</table>

The titre in ACH may reach 1/640 but they generally range from 1/80 to 1/320 and persist for a year. In viral hepatitis the titres are usually below 1/180 and are transient. The titres in PBC are also low, ranging from 1/10 to 1/40.

The IFA test will result in a cross-striation staining pattern of skeletal muscle. The percentages of patients with anti-striated antibodies vary with the clinical state:

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>% Anti-Str Abs</th>
</tr>
</thead>
<tbody>
<tr>
<td>All MG patients</td>
<td>40%</td>
</tr>
<tr>
<td>MG with Thymoma</td>
<td>90-100%</td>
</tr>
<tr>
<td>MG without Thymoma</td>
<td>30%</td>
</tr>
<tr>
<td>Thymoma without MG</td>
<td>25%</td>
</tr>
</tbody>
</table>

*Absence of anti-Str Abs effectively excludes thymoma.

Smooth muscle antibody (SMA) positive results are observed as bright diffuse cytoplasmatic staining of the smooth muscle layers of the muscular mucosae in the rat stomach. Fluorescence may also be evident in the capillary walls of the gastric layer and surrounding arteries or veins. Fluorescence of the other cellular antigens such as nucleioli, parietal cells or connective tissue should not be reported as positive SMA.

The titre is the highest dilution of the patient’s serum showing weak (1+) fluorescence of the muscular mucosa,

<table>
<thead>
<tr>
<th>Titre</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/10</td>
<td>Normal, negative</td>
</tr>
<tr>
<td>1/20-1/80</td>
<td>Positive, suggestive of liver disease</td>
</tr>
<tr>
<td>1/160 or greater</td>
<td>Suggestive of active chronic hepatitis</td>
</tr>
</tbody>
</table>

The titre in ACH may reach 1/640 but they generally range from 1/80 to 1/320 and persist for a year. In viral hepatitis the titres are usually below 1/180 and are transient. The titres in PBC are also low, ranging from 1/10 to 1/40.

The IFA test will result in a cross-striation staining pattern of skeletal muscle. The percentages of patients with anti-striated antibodies vary with the clinical state:

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>% Anti-Str Abs</th>
</tr>
</thead>
<tbody>
<tr>
<td>All MG patients</td>
<td>40%</td>
</tr>
<tr>
<td>MG with Thymoma</td>
<td>90-100%</td>
</tr>
<tr>
<td>MG without Thymoma</td>
<td>30%</td>
</tr>
<tr>
<td>Thymoma without MG</td>
<td>25%</td>
</tr>
</tbody>
</table>

*Absence of anti-Str Abs effectively excludes thymoma.